Merck returns to Alzheimer’s disease with $1.1B Cerevance pactR&D, TherapeuticsWith an investment valued at up to $1.1 billion, Merck is diving back into Alzheimer’s research through a collaboration with Cerevance. Read more August 9, 2022/by BioSpace https://www.pharmalive.com/wp-content/uploads/2020/11/Merck-Bolsters-COVID-19-Pipeline-with-OncoImmune-Acquisition-BioSpace-11-23-20.jpeg 350 625 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2022-08-09 12:15:572022-08-09 12:15:57Merck returns to Alzheimer’s disease with $1.1B Cerevance pact
